The landscape of employer-sponsored health insurance, a cornerstone of healthcare access for millions of working-age Americans, is facing unprecedented challenges, with small businesses disproportionately bearing the brunt of escalating costs. Preliminary analysis of rate filings for 2027 reveals a stark reality: insurers are seeking substantial premium increases, driven by a confluence of factors including rapidly rising medical expenditures, the burgeoning use of high-cost specialty drugs, and the lingering financial repercussions of federal legislation. This surge threatens to further destabilize an already fragile market, potentially pushing more small employers to the brink of discontinuing vital health benefits.
The Crisis in Small Group Health Insurance
Employer-sponsored health insurance serves as the primary source of healthcare coverage for approximately 165 million working-age adults in the United States. However, the financial burden of offering these plans is becoming increasingly untenable for businesses, particularly smaller enterprises that historically struggle to allocate sufficient resources for employee benefits. Data from the Kaiser Family Foundation (KFF) highlights this disparity: in the past year, only 51% of firms with fewer than 25 employees provided health insurance, a stark contrast to the 97% of companies with 200 or more employees that offered such coverage.
The implications of the current premium trajectory are significant. If the projected double-digit premium increases materialize next year, the already modest rate of small companies offering health benefits could plummet further. This would leave a substantial portion of the American workforce without employer-provided health coverage, exacerbating existing healthcare access issues and potentially increasing reliance on public programs or the individual market, which may present its own set of affordability challenges.
Insurers Demand Double-Digit Rate Hikes
A comprehensive analysis of preliminary rate filings from nearly 300 insurers across all 50 states and Washington D.C. for small group coverage—plans offered to employers with fewer than 50 employees—indicates a widespread demand for significant premium adjustments. The median proposed rate change stands at a concerning 14%, a figure that surpasses the 11% increases requested for 2026 and aligns with the substantial hikes proposed for plans within the Affordable Care Act (ACA) marketplaces.
Insurers attribute these aggressive requests to the escalating costs associated with underlying medical care and pharmaceuticals. They contend that the price of essential services, including hospitalizations and prescription drugs, has surged, while simultaneously, member utilization of these services has increased. This dual pressure on expenditure is forcing insurers to seek commensurate adjustments in premiums to maintain financial solvency and continue offering coverage.
"Costs for medical care and medications for our members have escalated rapidly, and spending is now growing at the fastest rate in more than a decade," stated Blue Cross and Blue Shield of Massachusetts in their rate request documentation. "The surge in spending is putting a heavy burden on our employer customers and members who are struggling to keep up with rising costs."
The Impact of Specialty Drugs and Emerging Therapies
A significant driver behind the escalating healthcare costs cited by insurers is the increasing demand and associated expenses of GLP-1 receptor agonists. Originally developed and prescribed for diabetes management, these medications have seen a dramatic rise in popularity for weight loss purposes and are showing promise in treating other medical conditions. The high price tags of these specialty drugs, coupled with their expanding application, are creating a substantial financial strain on healthcare systems and, consequently, on insurance providers.
While some insurers have begun to discontinue coverage for anti-obesity treatments due to the exorbitant cost of GLP-1s, this measure has not fully offset the overall increase in spending. The KFF analysis indicates that even with such policy adjustments, the utilization by a growing number of diabetes patients continues to drive up expenditures. This trend underscores a broader challenge in the pharmaceutical landscape, where innovative, high-cost therapies, while offering significant clinical benefits, pose a substantial affordability challenge for the healthcare system.
The Unforeseen Consequences of the No Surprises Act
Adding another layer of complexity to the premium increase equation is the impact of the No Surprises Act (NSA), a landmark consumer protection law enacted in 2020. The NSA aims to shield patients from unexpected medical bills, particularly for out-of-network services, by establishing a framework for insurers and providers to negotiate reimbursement rates. However, research and insurer filings suggest that the dispute resolution process mandated by the NSA may be contributing to higher costs.
According to the KFF review, providers have been prevailing in a majority of billing disputes, often securing payouts that significantly exceed in-network rates. This outcome translates into higher costs for insurers, which are now beginning to pass these increased expenses onto employers and plan members through higher premiums.
For instance, Oxford Health Insurance of New York and UnitedHealthcare Insurance Company of New York, both subsidiaries of the insurance giant UnitedHealthcare, cited the NSA as a reason for adding 0.8% to their rates for the upcoming year. This revelation comes on the heels of UnitedHealthcare reporting unexpectedly high spending in its commercial business during its second-quarter earnings call, with executives attributing a portion of this increase to the NSA. This suggests that the unintended financial consequences of the legislation are beginning to manifest across the insurance market.
The Shifting Market and the Rise of Alternative Funding Models
The escalating premiums in the fully-insured small group market are prompting many businesses to explore alternative coverage options. This exodus of employers, particularly those with healthier workforces, is contributing to a phenomenon known as risk pool erosion. As healthier individuals and employers opt for different plans or self-insure, the remaining pool of insured individuals may comprise a higher proportion of those with greater healthcare needs, thus driving up the average cost of care and, consequently, future premium increases for those who remain in the traditional fully-insured market.
The KFF reports a notable decline in the number of individuals covered by fully-insured small group plans, dropping from 17 million in 2013 to 10 million in 2024. Despite this decrease, overall coverage rates among small business employees have remained relatively stable. This suggests that many employers are not abandoning health benefits altogether but are instead migrating towards self-funded or level-funded products.
Level-funded plans, in particular, have gained traction among small businesses. In these arrangements, employers pay a fixed monthly premium, and if the actual medical claims incurred by their employees are lower than anticipated, the employer may receive a refund. These plans are often perceived as more cost-effective for small businesses with a healthier employee population.
However, these alternative models come with their own set of drawbacks and potential risks. Crucially, level-funded plans are generally not subject to the comprehensive benefit requirements mandated by the Affordable Care Act. This regulatory distinction allows insurers to assess the health profile of a potential group of employees and adjust premiums accordingly, or even decline coverage, based on pre-existing medical conditions and other health factors.
"Continued growth in the popularity of alternative coverage options for small businesses, like level-funded plans, has the potential to further erode the fully-insured small group risk pool and could contribute to future premium increases for small businesses, particularly those with sicker employees who may not qualify for or are priced out of a level-funded arrangement," KFF researchers cautioned in their analysis. This dynamic could create a tiered system where healthier employees benefit from more flexible and potentially cheaper options, while those with greater health needs face rising costs or limited access to coverage.
Broader Implications and Future Outlook
The current trajectory of premium increases in the small group market carries significant implications for the broader U.S. healthcare system. For small businesses, the rising cost of health insurance represents a direct threat to their operational sustainability and their ability to attract and retain talent. Many may be forced to absorb these costs, leading to reduced investment in other areas of their business, or pass them on to employees through higher deductibles, copayments, and coinsurance, effectively reducing the value of their benefits packages.
For employees, these increases can translate into reduced disposable income and difficult choices between healthcare coverage and other essential needs. The potential for further erosion of the fully-insured market could also lead to a more fragmented and less equitable healthcare system, where access to comprehensive coverage is increasingly determined by an employer’s size and the perceived health status of its workforce.
The situation is further compounded by other market forces. For instance, insurers in the ACA marketplaces are also contending with proposed rate hikes and the expiration of enhanced federal subsidies, which previously helped to lower out-of-pocket costs for eligible individuals. This parallel pressure on both employer-sponsored and individual market plans suggests a systemic challenge within the U.S. healthcare financing system.
Looking ahead, policymakers and industry stakeholders face a critical juncture. Addressing the root causes of rising healthcare costs—including prescription drug pricing, hospital consolidation, and the complex interplay of federal regulations—will be essential to stabilizing the employer-sponsored insurance market. Innovative solutions that promote affordability, maintain access to quality care, and ensure the long-term viability of health benefits for all Americans will be paramount in navigating this escalating crisis. The coming years will likely see increased scrutiny on insurance pricing, the effectiveness of legislative interventions, and the ongoing evolution of healthcare delivery and financing models.
About the Author
